Plague: Disease, Management, and Recognition of Act of Terrorism

Infectious Disease Clinics of North America

Volumn 20, Issue 2, 2006, Pages 273-287

  Koirala, Janak ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; DNA VACCINE; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; MOXIFLOXACIN; OFLOXACIN; PLAGUE VACCINE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; VIRULENCE FACTOR;

BIOLOGICAL WARFARE; CHINA; DIAGNOSTIC TEST; DRUG SAFETY; EPIDEMIC; FATALITY; FLUID RESUSCITATION; FLUORESCENT ANTIBODY TECHNIQUE; GENOMICS; HUMAN; IMMUNIZATION; INFECTION PREVENTION; JAPAN; NONHUMAN; PATHOGENESIS; PHYLOGENY; PLAGUE; PNEUMONIA; POLYMERASE CHAIN REACTION; REVIEW; SAFETY; SEROLOGY; TERRORISM; UNITED STATES; USSR; WORLD HEALTH ORGANIZATION; YERSINIA PESTIS; ZOONOSIS;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BIOTERRORISM; CHILD; DISEASE OUTBREAKS; HUMANS; PLAGUE; VIRULENCE; YERSINIA PESTIS;

EID: 33744785412     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.02.004     Document Type: Review

References (49)

1. Achtman M., Morelli G., Zhu P., et al. Microevolution and history of the plague bacillus, Yersinia pestis. Proc Natl Acad Sci U S A 101 (2004) 17837-17842
2. Kostis K.P. In search of the plague: the Greek peninsula faces the Black Death, 14th to 19th centuries. Dynamis 18 (1998) 465-478
3. Dols M.W. The second plague pandemic and its recurrences in the Middle East: 1347-1894. J Econ Soc Hist Orient 22 (1979) 162-189
4. WHO report on global surveillance of epidemic-prone infectious diseases (2000), World Health Organization, Geneva
5. Dennis D.T., Gage K.L., Gratz N., et al. Plague manual: epidemiology, distribution, surveillance and control (1999), World Health Organization, Geneva 11-171
6. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 1 (1997) 35-66
7. Gage K.L., Dennis D.T., Orloski K.A., et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis 30 (2000) 893-900
8. Centers for Disease Control and Prevention. ASM, APHL basic protocols for level A laboratories for the presumptive identification of Yersinia pestis (2001), CDC, Atlanta
9. Achtman M., Zurth K., Morelli G., et al. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A 96 (1999) 14043-14048
10. Parkhill J., Wren B.W., Thomson N.R., et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 413 (2001) 523-527
11. Deng W., Burland V., Plunkett G., et al. Genome sequence of Yersinia pestis KIM. J Bacteriol 184 (2002) 4601-4611
12. Drancourt M., Roux V., Dang L.V., et al. Genotyping, Orientalis-like Yersinia pestis, and plague pandemics. Emerg Infect Dis 9 (2004) 1585-1592
13. Hinnebusch B.J. The evolution of flea-borne transmission in Yersinia pestis. Curr Issues Mol Biol 7 (2005) 197-212
14. Woolhouse M.E., Taylor L.H., and Haydon D.T. Population biology of multihost pathogens. Science 292 (2001) 1109-1112
15. Song Y., Tong Z., Wang J., et al. Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res 11 3 (2004) 179-197
16. Hummel S., Schmidt D., Kremeyer B., et al. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 6 (2005) 371-374
17. Mecsas J., Franklin G., Kuziel W.A., et al. Evolutionary genetics: CCR5 mutation and plague protection. Nature 427 (2004) 606
18. McGovern T.W., and Friedlander A. Plague. In: Zajtchuk R., and Bellamy R.F. (Eds). Medical aspects of chemical and biological warfare (1997), Office of the Surgeon General, Bethesda 479-502
19. Dennis D., and Meier F. Plague. In: Horsburgh C.R., and Nelson A.M. (Eds). Pathology of emerging infections (1997), ASM Press, Washington 21-47
20. Philipovskiy A.V., Cowan C., Wulff-Strobel C.R., et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun 73 (2005) 1532-1542
21. Hill J., Copse C., Leary S., et al. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71 (2003) 2234-2238
22. Anderson Jr. G.W., Worsham P.L., Bolt C.R., et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 56 (1997) 471-473
23. Pujol C., and Bliska J.B. Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol 114 (2005) 216-226
24. Viboud G.I., and Bliska J.B. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 59 (2005) 69-89
25. Kukkonen M., Suomalainen M., Kyllonen P., et al. Lack of O-antigen is essential for plasminogen activation by Yersinia pestis and Salmonella enterica. Mol Microbiol 51 (2004) 215-225
26. Bossi P., Tegnell A., Baka A., et al. Bichat guidelines for the clinical management of plague and bioterrorism-related plague. Euro Surveill 9 (2004) E5-E6
27. Cleri D.J., Vernaleo J.R., Lombardi L.J., et al. Plague pneumonia disease caused by Yersinia pestis. Semin Respir Infect 12 (1997) 12-23
28. McGovern T.W., and Friedlander A.M. Plague. In: Sidell F.R., Takafuji E.T., and Franz D.R. (Eds). Textbook of military medicine: medical aspects of chemical and biological warfare (1997), Borden Institute, Washington
29. Inglesby T.V., Dennis D.T., Henderson D.A., et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283 (2000) 2281-2290
30. WHO. Health aspects of chemical and biological weapons (1970), WHO, Geneva
31. Lowell J.L., Wagner D.M., Atshabar B., et al. Identifying sources of human exposure to plague. J Clin Microbiol 43 (2005) 650-656
32. CDC. Laboratory testing criteria for diagnosis of plague. Available at: http://www.cdc.gov/ncidod/dvbid/plague/lab-test-criteria.htm. Accessed January 13, 2006.
33. Chanteau S., Rahalison L., Ralafiarisoa L., et al. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet 361 (2003) 211-216
34. Chanteau S., Rahalison L., Ratsitorahina M., et al. Early diagnosis of bubonic plague using F1 antigen capture ELISA assay and rapid immunogold dipstick. Int J Med Microbiol 290 (2000) 279-283
35. Tomioka K., Peredelchuk M., Zhu X., et al. A multiplex polymerase chain reaction microarray assay to detect bioterror pathogens in blood. J Mol Diagn 7 (2005) 486-494
36. Boulanger L.L., Ettestad P., Fogarty J.D., et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. Clin Infect Dis 38 (2004) 663-669
37. Bonacorsi S.P., Scavizzi M.R., Guiyoule A., et al. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother 38 (1994) 481-486
38. Byrne W.R., Welkos S.L., Pitt M.L., et al. Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob Agents Chemother 42 (1998) 675-681
39. Steward J., Lever M.S., Russell P., et al. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. Int J Antimicrob Agents 24 (2004) 609-612
40. Russell P., Eley S.M., Green M., et al. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother 41 (1998) 301-305
41. Russell P., Eley S.M., Bell D.L., et al. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J Antimicrob Chemother 37 (1996) 769-774
42. Galimand M., Guiyoule A., Gerbaud G., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337 (1997) 677-680
43. Ryzhko I.V., Shcherbaniuk A.I., Skalyga E., et al. Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones. Antibiot Khimioter 48 (2003) 19-23
44. Kasatkina I.V., Shcherbaniuk A.I., Makarovskaia L.N., et al. Chromosomal resistance of plague agent to quinolones. Antibiot Khimioter 36 (1991) 35-37
45. Gage K.L., Denis D.T., and Tsai T.F. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 45 (1996) 1-15
46. Titball R.W., and Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4 (2004) 965-973
47. Jefferson T., Demicheli V., and Pratt M. Vaccines for preventing plague. Cochrane Database Syst Rev 2 (2000) CD000976
48. Williamson E.D., Flick-Smith H.C., Lebutt C., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 (2005) 3598-3608
49. Wang S., Heilman D., Liu F., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 (2004) 3348-3357